Monopar Therapeutics.
biopharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 23
What's happening
One to three months ago
-
Analyst ratings published on MarketBeat for Monopar Therapeutics, which trades on the Nasdaq stock exchange.Some support2 reports
-
Monopar Therapeutics, having taken over sponsorship of ALXN1840 from Alexion, is enrolling in clinical trials and must comply with federal regulations.Some support5 reports2 developments inside
-
Monopar Therapeutics submitted a New Drug Application (NDA) to the FDA for review.Some support1 report
Gone quiet
No new reports in 90+ daysNo events began in the chosen period. Widen it, or reset.
Around Monopar Therapeutics this week
News at the entities that move Monopar Therapeutics most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Monopar Therapeutics
-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves Monopar Therapeutics
-
Manufacturers Life Insurance Company TransactionalManufacturers Life Insurance Company purchased a new stake in Telos shares, a company serving customers in the United States.Moves Monopar Therapeutics
-
Cantor Fitzgerald Mentioned togetherAnalyst firm lowered price targets on Automatic Data Processing (ADP) stock on June 6, 2026.Moves Monopar Therapeutics
-
Nasdaq Shared contextApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Monopar Therapeutics
-
Morgan Stanley Mentioned togetherFinancial firms including Morgan Stanley, Truist Financial, Jefferies Financial Group, and CIBC issued rating and price objective updates for Clearway Energy.Moves Monopar Therapeutics
Connections
The 8 strongest of 23, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
FDA formally regulates Monopar Therapeutics, granting designations and requiring compliance with federal regulations.
-
Chandler Robinson Structural
Chandler Robinson serves as the CEO of Monopar Therapeutics and holds a 1.1% equity stake in the company.
-
SEC Structural
Monopar Therapeutics is required to file disclosures with the SEC as part of regulatory compliance.
-
Manufacturers Life Insurance Company Transactional
A purchased a new position in company shares of B.
-
Nasdaq Shared context
Monopar Therapeutics is listed and trades its shares on the Nasdaq stock exchange.
-
Cantor Fitzgerald Mentioned together
Cantor Fitzgerald provides research reports and ratings that influence Monopar Therapeutics.
-
Morgan Stanley Mentioned together
Morgan Stanley provides analyst ratings and price targets for Monopar Therapeutics.
-
MarketBeat Mentioned together
MarketBeat publishes financial and analyst ratings concerning Monopar Therapeutics.
History
Events by the month they beganJune 2026
5 events- Analyst ratings published on MarketBeat for Monopar Therapeutics, which trades on the Nasdaq stock exchange.
- Monopar Therapeutics, having taken over sponsorship of ALXN1840 from Alexion, is enrolling in clinical trials and must comply with federal regulations.
- The FDA granted Rare Pediatric Disease designation to Monopar Therapeutics.
- Monopar Therapeutics shares began trading on the Nasdaq stock exchange.
- Monopar Therapeutics held an ANA meeting in Baltimore on September 3, 2025.